Niloofar Yari, MD
Neuromuscular Medicine · Dallas, TXNPI 1396165379
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 242 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 30 manufacturers reported payments, led by AbbVie at 31.0% of the total. 2025 is the largest year on record at $1,407, 6.2 times the $228 reported in 2019.
Across 242 payments — averaging $19.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- UCB, Inc.$1K
- Pfizer$330
- Acadia Pharmaceuticals Inc$262
- GE HealthCare$117
- Avanir Pharmaceuticals, Inc.$111
- plus $1K from 24 others
Across 17 payments — averaging $1735.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ares Trading SA$27K
- Merck Healthcare Kgaa$2K
What the payments were for
- Food & beverage$4,650100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 112 | $1,444 |
| UCB, Inc. | 42 | $1,383 |
| Pfizer | 19 | $330 |
| Acadia Pharmaceuticals Inc | 11 | $262 |
| GE HealthCare | 7 | $117 |
| Avanir Pharmaceuticals, Inc. | 6 | $111 |
| Lundbeck LLC | 5 | $108 |
| Amgen | 4 | $92 |
| Amneal Pharmaceuticals LLC | 4 | $80 |
| Teva Pharmaceuticals USA, Inc. | 3 | $78 |
| Biogen | 3 | $68 |
| Catalyst Pharmaceuticals, Inc. | 3 | $60 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $49 |
| Avion Pharmaceuticals | 2 | $48 |
| Cala Health, Inc. | 1 | $45 |
| Octapharma USA, Inc. | 2 | $39 |
| Johnson & Johnson | 2 | $37 |
| Sanofi | 1 | $36 |
| Neurelis, Inc. | 2 | $36 |
| EMD Serono, Inc. | 1 | $35 |
| Neurocrine Biosciences, Inc. | 1 | $32 |
| AstraZeneca | 1 | $23 |
| Abbott | 1 | $23 |
| Akcea Therapeutics, Inc. | 1 | $21 |
| SK Life Science, Inc. | 1 | $19 |
| Hospira, Inc. | 1 | $18 |
| Lilly USA, LLC | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Harmony Biosciences LLC | 1 | $14 |
| Ipsen Biopharmaceuticals, Inc | 1 | $13 |
How this compares
Too few neuromuscular medicine providers in Texasto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FirdapseAmifampridine Phosphate | 26 | $998,098 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 50 | $366,424 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 36 | $334,608 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 39 | $324,609 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 11 | $152,046 |
| Nurtec OdtRimegepant Sulfate | 20 | $47,359 |
| UbrelvyUbrogepant | 25 | $34,131 |
| Aimovig AutoinjectorErenumab-Aooe | 17 | $13,079 |
| Pyridostigmine Bromide | 36 | $4,100 |
| Mycophenolate Mofetil | 21 | $2,441 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 44 | $2,121 |
| Gabapentin | 91 | $2,069 |
| Duloxetine Hcl | 64 | $1,839 |
| Oxcarbazepine | 32 | $1,789 |
| Levetiracetam | 39 | $1,574 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Catalyst Pharmaceuticals, Inc.Firdapse | $60 | $998,09826 claims |
| PfizerOctagam, Nurtec Odt | $330 | $413,78370 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $14 | $334,60836 claims |
| AbbVieUbrelvy | $1,444 | $34,13125 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide, Mycophenolate Mofetil | $80 | $6,54257 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few neuromuscular medicine providers in Texason file to place this against a meaningful peer group, so we don't.
Other neuromuscular medicine in Dallas
- Hakam AsaadDallas$8K
- Yessar HussainAustin$127K
- Matthew WicklundSan Antonio$110K
- Ashley AndersonHouston$76K
- Ratna Bhavaraju SankaSan Antonio$56K
- Suur BilicilerHouston$37K
- Darine KassarSugar Land$6K
- Anita MadanHouston$3K
- George CreelTemple$3K
- Cassie ChanSan Antonio$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.